VeonGen Aligns with FDA on Phase 3 Design for Stargardt Gene Therapy

VeonGen Therapeutics announced on November 5, 2026, that it has reached alignment with the FDA on the pivotal phase 3 design and manufacturing strategy for VG801, its investigational dual-adeno-associated virus (AAV) gene therapy for Stargardt disease and other ABCA4-associated retinal dystrophies.¹ The company also reported that VG801 produced sustained functional vision improvements through month 12 in its ongoing phase 1/2 study.¹

"FDA alignment on the pivotal Phase 3 clinical and CMC strategy represents an important de-risking milestone for VG801 and a significant step toward global pivotal development," said Caroline Man Xu, PhD, co-founder and CEO of VeonGen Therapeutics.¹

What did the FDA alignment cover?

VeonGen reached alignment with the FDA at a regenerative medicine advanced therapy (RMAT) Type B meeting on key clinical and chemistry, manufacturing, and controls (CMC) aspects of the VG801 pivotal phase 3 program.¹ According to the company, the meeting minutes document alignment on the pivotal study design, including the primary endpoint, study duration, and control arm.¹ On CMC, the alignment covers use of the existing clinical batch for the pivotal study and key aspects of the commercial manufacturing strategy.¹

VeonGen is also advancing the Virtual Reality Visual Test (VRVT) through the FDA's Rare Disease Endpoint Advancement pilot program to support its development as a functional vision measure in Stargardt disease.¹ VG801 has received phase 1/2 clinical trial authorizations in Europe and China.¹

What did the phase 1/2 data show?

The first-in-human phase 1/2 study (NCT07002398) has dosed 15 patients across 3 dose cohorts, including adults and pediatric patients.¹,² VeonGen reported consistent functional improvements through month 12 across best-corrected visual acuity (BCVA), VRVT, and microperimetry fixation.¹

Among the 13 patients with measurable baseline BCVA, all showed improvements from baseline to month 6 or month 12.¹ Of those, 11 achieved gains of at least 5 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, including 7 who gained at least 10 letters and 4 who gained at least 15 letters.¹ The company said these findings, along with stable retinal structures and a favorable safety profile to date, support the therapy's potential.¹

How does VG801 work?

VG801 combines VeonGen's vgAAV2 capsid with its vgRNA REVeRT (Reconstitution Via mRNA Trans-splicing) technology to deliver and reconstitute a full-length functional human ABCA4 gene in retinal photoreceptor cells.¹ Because the ABCA4 gene exceeds the cargo limit of a single AAV vector, the dual-AAV approach splits the gene across 2 vectors and joins the fragments at the messenger RNA level through trans-splicing.³ VeonGen said the design is intended to address the genetic cause of Stargardt disease across different ABCA4 mutations, offering a potentially genotype-agnostic approach.¹ VG801 holds FDA RMAT, rare pediatric disease, and orphan drug designations.¹

Why does VG801 matter for Stargardt disease?

Stargardt disease is one of the most common inherited macular dystrophies, affecting an estimated 1 in 8000 to 10,000 people worldwide.¹ Caused by mutations in the ABCA4 gene, it leads to progressive central vision loss that often begins in childhood or adolescence and can progress to legal blindness.¹ There are no approved treatments for the disease.¹

What are the limitations?

The functional improvements come from a small, open-label, first-in-human study without a control arm, and 13 patients were evaluable for BCVA. Detailed results have not been published in a peer-reviewed journal. RMAT alignment on a pivotal design does not guarantee a successful trial or approval, and the controlled phase 3 study has not begun. VeonGen did not disclose the planned phase 3 primary endpoint, study duration, or enrollment.

References

1. VeonGen Therapeutics. VeonGen announces FDA alignment on pivotal Phase 3 development and clinical progress of VG801 for Stargardt disease. Press release. Published November 5, 2026. Accessed November 5, 2026. https://www.globenewswire.com/news-release/2026/11/05/3396355/0/en/veongen-announces-fda-alignment-on-pivotal-phase-3-development-and-clinical-progress-of-vg801-for-stargardt-disease.html
2. Safety and preliminary efficacy of VG801 in patients with ABCA4 mutation-associated retinal dystrophy (Stargardt disease). ClinicalTrials.gov; NCT07002398. Updated September 2, 2026. Accessed November 5, 2026. https://clinicaltrials.gov/study/NCT07002398
3. Riedmayr LM, Hinrichsmeyer KS, Thalhammer SB, et al. mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy. Nat Commun. 2023;14(1):6578. doi:10.1038/s41467-023-42386-0